Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene laherparepvec plus pembrolizumab after anti-PD-1 progression in unresectable or metastatic melanoma
NL-OMON54763Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec and pembrolizumab in melanoma, sponsored by Amgen. Primary endpoint: Objective response rate. Started Nov 2020; status: completed.
02
Drugs
talimogene laherparepvecpembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON54763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54763.